Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Starpharma Holdings Limited (SPHRF)
OTHER OTC:SPHRF
Holding SPHRF?
Track your performance easily
SPHRF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.05 - $0.13
Previous Close$0.06
Volume20.25K
Average Volume (3M)8.91K
Market Cap
$27.62M
Enterprise Value-$372.67K
Total Cash (Recent Filing)AU$49.92M
Total Debt (Recent Filing)AU$8.19M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Mar 04, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding408,852,447
10 Day Avg. Volume0
30 Day Avg. Volume8,906
Standard Deviation0.18
R-Squared0.12
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)6.73
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Starpharma Holdings Limited News
PremiumCompany Announcements
Starpharma Director Boosts Stake with On-Market Purchase
PremiumCompany Announcements
Starpharma Secures $5.5M R&D Tax Boost
PremiumCompany Announcements
Allan Gray No Longer a Major Starpharma Investor
PremiumCompany Announcements
Starpharma Director Buys Up Company Shares
PremiumCompany Announcements
Starpharma Director Bolsters Shareholdings
PremiumCompany Announcements
Starpharma Stake Reduced by Allan Gray Australia
PremiumCompany Announcements
Starpharma Releases Governance Documents
PremiumCompany Announcements
Starpharma Reports Revenue Surge and Lower LossesOptions Prices
Currently, No data available
---
Ownership Overview
8.12% Insiders
2.40% Mutual Funds
<0.01% Other Institutional Investors
89.48% Public Companies and
Individual Investors
SPHRF FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest stock price was $0.05 and its highest was $0.13 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Currently, no data Available
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Mar 04, 2025 which is in 165 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Starpharma Holdings Limited released its earnings results on Aug 21, 2024. The company reported -$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.011.
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 417,367,680 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Starpharma Holdings Limited reported an EPS of -$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in SPHRF
---
Starpharma Holdings Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
SPHRF Sentiment 80%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $149.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.48%
12-Months-Change
Fundamentals
Return on Equity
-25.59%
Trailing 12-Months
Asset Growth
-29.09%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Its programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
---
Technical Analysis
---